Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension
NEJM 375:1119-1130,1183, Hutchinson, P.J.,et al, 2016
Early Transfer of Patients with Stroke to Comprehensive Centers is Necessary
Stroke 45:3748-3749,3752, Sheth, K.N., 2014
Early Transfer of Patients with Stroke to Comprehensive Stroke Centers is not Necessary
Stroke 45:3750-3751,3752, Langhorne, P., 2014
Tumor Necrosis Factor-Alpha Inhibitors: Risk of Malignancy
UpToDate January, Stone, J.H., 2013
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
PANDAS
www.medlink.com,Feb, Erfe,M.C.B., 2011
Risk of Dementia and AD with Prior Exposure to NSAIDs in an Elderly Community-Based Cohort
Neurol 72:1899-1905,1884, Breitner,J.C.S.,et al, 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Assessment of Declofenac or Spinal Manipulative Therapy, Or Both, in Addition to Recommended First-Line Treatment for Acute Low Back Pain: A Randomised Controlled Trial
Lancet 370:1638-1643, Hancock,M.J., et al, 2007
Expanding Indications for Statins in Cerebral Ischemia
Arch Neurol 62:67-72,23, Ovbiagele,B.,et al, 2005
Thrombosis of the Cerebral VEins and Sinuses
NEJM 352:1791-1798, Stam,J., 2005
Steroids Have No Role in Stroke Therapy
Stroke 35:229-231, Poungvarin,N.,et al, 2004
Steroids May Have a Role in Stroke Therapy
Stroke 35:228-229,230, Norris,J.W., 2004
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Stiff-Person Syndrome
The Neurologist 10:131-137, Murinson,B.B., 2004
Potassium Channel Antibody-Associated Encephalopathy: A Potentially Immunotherapy-Responsive Form of Limbic Encepahlitis
Brain 127:701-712, Vincent,A.,et al, 2004
Surgical Decompression of Patients with Large Middle Cerebral Artery Infarcts is Effective
Stroke 34:2304-2305,2307, Schwab,S.&Hacke,W., 2003
Surgical Decopression of Patients With Large Middle Cerebral Artery Infarcts is Effective:Not Proven
Stroke 34:2305-2306,2307, Brown,M.M., 2003
Critical Illness Myopathy
Muscle Nerve 23:1785-1788, Lacomis,D.,et al, 2000
Posttraumatic Headache-A Myth?
Arch Neurol 57:1778-1780, Warner,J.S., 2000
Posttraumatic Headache
Arch Neurol 57:1776-1778,1780, Saper,J.R., 2000
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
The Therapeutic Dilemma of Inclusion Body Myositis
Neurol 48:567-568, Barohn,R.J., 1997
Do NMDA Antagonists Prevent Neuronal Injury? Yes
ARch Neurol 49:418-420, Albers,G.W.,et al, 1992
Eclampsia
NEJM 289:976, 1973; 290:344974., Jewett,J.F., 1974